Shares of Moderna Inc. fell sharply on Monday after the biotech firm projected a steep decline in 2025 revenues, falling below Wall Street expectations. The company, known for its COVID-19 vaccine ...

Moderna made a lot of money during the pandemic, but its post-pandemic prospects look bleak. Sales in 2025 could be down more than half from 2024 levels, according to Moderna's latest guidance ...

Moderna projects $1.5 billion-$2.5 billion in 2025 revenue, with cash and investments estimated at $6 billion by year-end. 2024 product sales are approximately $3 billion-$3.1 billion, driven by $ ...

Earlier this month, Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s lackluster vaccine sales in COVID-19 and respiratory ...

You may be able to get away with using a lighter lotion in the summer, especially if it does have powerful hydrating ingredients, but typically for those who have year-round dryness or a condition ...

Drug maker Moderna's stock plunged more than 17% in pre-market trading on Monday after the company slashed its sales outlook by $1 billion. The company reported product sales of $3 to $3.1 billion ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Moderna shares dropped as much as 22 per cent on Monday after the US biotech group’s sales forecasts ...

It wasn’t too long before I realized my body lotion wasn’t going to cut it, especially on the go. Nearly four years — and lots of hand creams — later, I’ve become well versed in what ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Yahoo Finance's Brad Smith reviews Wednesday's trending stocks on Wealth. Moderna's (MRNA) price target slashed to $38 from $70 by Morgan Stanley (MS), implying an 11% potential upside based on ...

This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid ...